Full Text View  
  Tabular View  
  Contacts and Locations  
  No Study Results Posted  
  Related Studies  
Topiramate for Binge Eating Disorder Among Adolescents
This study has been completed.
Sponsored by: The Zucker Hillside Hospital
Information provided by: The Zucker Hillside Hospital
ClinicalTrials.gov Identifier: NCT00768677
  Purpose

This is a study of topiramate to see whether topiramate decreases binge eating behavior among adolescents and young adults. The investigators did also checked whether topiramate affected cognitive function or not.


Condition Intervention
Eating Disorders
Bulimia Nervosa
Drug: topiramate

MedlinePlus related topics: Eating Disorders
Drug Information available for: Topiramate
U.S. FDA Resources
Study Type: Interventional
Study Design: Treatment, Single Group Assignment
Official Title: Open-Label Study of Topiramate for Binge Eating Disorder and Bulimia Nervosa Among Adolescents

Further study details as provided by The Zucker Hillside Hospital:

Study Start Date: July 2003
  Eligibility

Ages Eligible for Study:   12 Years to 23 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

Subjects (aged 12 to 23) were included if they

  • Met the criteria of bulimia nervosa or eating disorder NOS with binge-eating behavior in DSM-IV-TR,
  • Had weight > or = 100th % of expected body weight for their age,
  • Engaged in binge eating at least once a week for 9 out of the 12 weeks prior to the study entry, and
  • Were judged by a clinician to be stable enough to be treated for their psychiatric condition as an outpatient (i.e, no acute suicidality, hallucination, unstable vital signs or persistently abnormal laboratory results due to eating disorder).

Exclusion Criteria:

  • Subjects whose psychotropic medications had been changed within 4 weeks prior to the entry or who had started psychotherapy within 3 months prior to the entry were excluded.
  • Subjects were also excluded if they were taking carbonic anhydrase inhibitors, carbamazepine, phenytoin, phenobarbital, valproic acid, evening primrose oil or oral contraceptives.
  • Other exclusion criteria were: history of substance use disorders within the 6 months prior to study, IQ < or = 70, medical conditions causing weight loss (i.e., hyperthyroidism, diabetes mellitus type 1, malignancy) or that contra indicate treatment with topiramate (nephrolithiasis or glaucoma), history of non response or poor tolerance to topiramate in the past and history of non-adherence to medication treatment.
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00768677

Locations
United States, New York
The Zucker Hillside Hospital
Glen Oaks, New York, United States, 11004
Sponsors and Collaborators
The Zucker Hillside Hospital
  More Information

Responsible Party: The Zucker Hillside Hospital ( Ema Saito )
Study ID Numbers: 03-04-063
Study First Received: October 7, 2008
Last Updated: October 7, 2008
ClinicalTrials.gov Identifier: NCT00768677  
Health Authority: United States: Institutional Review Board

Keywords provided by The Zucker Hillside Hospital:
binge eating behavior
adolescents

Study placed in the following topic categories:
Signs and Symptoms
Bulimia Nervosa
Signs and Symptoms, Digestive
Mental Disorders
Bulimia
Topiramate
Eating Disorders
Hyperphagia

Additional relevant MeSH terms:
Anti-Obesity Agents
Pathologic Processes
Disease
Therapeutic Uses
Physiological Effects of Drugs
Protective Agents
Neuroprotective Agents
Central Nervous System Agents
Pharmacologic Actions
Anticonvulsants

ClinicalTrials.gov processed this record on January 15, 2009